Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Ronald Kronemann who wrote (854)	5/24/1999 4:17:00 AM
From: Ronald Kronemann	Read Replies (1) \| Respond to of 1728

another collaboration! deCODE is using genetic heritage of iceland which is documented since several hundred years. A huge opportunity to discover gene-related diseases. A couple of months ago there was an article in a german magazine covering popular sciences (KONR@D, see also konrad.stern.de for the actual issue, but they don't provide text from older ones) about this company. I am happy to hear about this partner (and that I added some cheap shares last week). Ronald deCODE genetics Enters Strategic Relationship with Affymetrix REYKJAVIK, Iceland, May 24 /PRNewswire/ -- deCODE genetics, Inc. today announced that they have entered into an agreement with Affymetrix (Nasdaq: AFFX - news) to allow deCODE access to GeneChip® technology for use in gene expression monitoring and genotyping applications. deCODE and Affymetrix plan to continue their collaborative work focused on optimizing chip based SNP genotyping applications. ''We are pleased that our work with Affymetrix on its SNP genotyping initiative has been expanded to include access to gene expression arrays,'' stated Kari Stefansson, President and Chief Executive Officer of deCODE genetics, Inc. ''Access to this technology, coupled with deCODE's unique population based approach now provides us with a powerful solution for performing and analyzing array-based gene expression experiments. This represents a new entry for deCODE which is consistent with our objectives to augment our existing technology portfolio to include alternative gene discovery and gene functionality tools. '' ''deCODE genetics has been an important collaborator on our HuSNP assay, our first large-scale genotyping tool,'' stated Stephen P.A. Fodor, Ph.D., President and Chief Executive Officer of Affymetrix. ''Because of its unique access to the Icelandic population, deCODE can give us insight into population genetics that will be extremely valuable to our product development efforts. This relationship will include expression technology will be equally important as we continue our efforts to integrate expression and genotyping products.'' Based in Reykjavik, Iceland, deCODE genetics is a population-based genomic company, conducting research in the genetics of common diseases. The mission of deCODE genetics is to use human genetics and genomics to acquire new knowledge about health and disease, and work with pharmaceutical companies and healthcare providers to develop novel methods to identify, treat and prevent diseases. deCODE operates one of the most technologically advanced, high- throughput genotyping laboratories in the world. Additional information on deCODE can be found at www.decode.is. SOURCE: deCODE genetics, Inc.